Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480

Many tyrosine kinase inhibitors (TKIs) have failed to reach human use due to insufficient activity in clinical trials. However, the failed TKIs may still benefit patients if their other kinase targets are identified by providing treatment focused on syndromes driven by these kinases. Here, we search...

Descripción completa

Detalles Bibliográficos
Autores principales: Gudernova, Iva, Balek, Lukas, Varecha, Miroslav, Kucerova, Jana Fialova, Kunova Bosakova, Michaela, Fafilek, Bohumil, Palusova, Veronika, Uldrijan, Stjepan, Trantirek, Lukas, Krejci, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752523/
https://www.ncbi.nlm.nih.gov/pubmed/29312610
http://dx.doi.org/10.18632/oncotarget.22674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752523/
https://www.ncbi.nlm.nih.gov/pubmed/29312610
http://dx.doi.org/10.18632/oncotarget.22674

Ejemplares similares